We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oncimmune Holdings Plc | LSE:ONC | London | Ordinary Share | GB00BYQ94H38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -2.13% | 23.00 | 22.00 | 24.00 | 24.00 | 24.00 | 24.00 | 86,635 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 1.47M | -6.15M | -0.0830 | -2.89 | 17.79M |
TIDMONC
RNS Number : 3806W
Oncimmune Holdings PLC
11 December 2023
11 DECEMBER 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Director/PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry, has been notified that on 8 December 2023, Mr Martin Gouldstone, PDMR and Chief Executive Officer, purchased 36,023 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") at a price of GBP0.2725 per share.
Following this transaction Mr Gouldstone has a total interest in the Company of 36,023 Ordinary Shares, representing approximately 0.05 per cent of the Company's issued share capital of 74,142,147. In addition, Mr Gouldstone holds options over 589,971 Ordinary Shares, representing approximately 0.8 per cent of the Company's issued share capital.
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.
Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them.
Details of the person discharging managerial responsibilities 1 / person closely associated a) Name Mr Martin Gouldstone -------------------------------------- -------------------------------------- Reason for the notification 2 ------------------------------------------------------------------------------ a) Position/status Chief Executive Officer -------------------------------------- -------------------------------------- b) Initial notification Initial Notification /Amendment -------------------------------------- -------------------------------------- Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor ------------------------------------------------------------------------------ a) Name Oncimmune Holdings plc -------------------------------------- -------------------------------------- b) LEI 213800HCYIWT6YPI1I02 -------------------------------------- -------------------------------------- Details of the transaction(s): section to be repeated 4 for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------------------------------------------------------------------------------ a) Description of the Ordinary Shares of GBP0.01 each financial instrument, type of instrument Identification code ISIN: GB00BYQ94H38 b) Nature of the transaction Purchase of Ordinary Shares -------------------------------------- -------------------------------------- c) Price(s) and volume(s) ----------------- ---------------- Price(s) Volume(s) ----------------- ---------------- GBP0.2725 36,023 ------------------------------------------------------------- ---------------- d) Aggregated information N/A - single transaction - Aggregated volume - Price e) Date of the transaction 8 December 2023 -------------------------------------- -------------------------------------- f) Place of the transaction London Stock Exchange, AIMX -------------------------------------- --------------------------------------
For further information:
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Broker)
Phil Davies, Harry Gooden, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a global leader in immune biomarkers and immunodiagnostics, offering autoantibody biomarker profiling in immunooncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS(TM) technology platform, the Company provides insights and analytics to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy.
Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHEFLFFXLLFFBB
(END) Dow Jones Newswires
December 11, 2023 10:12 ET (15:12 GMT)
1 Year Oncimmune Chart |
1 Month Oncimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions